TAP 311
/ Novartis
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 20, 2012
Safety, tolerability, pharmacokinetics and pharmacodynamics of TAP311 in healthy subjects and dyslipidemic patients
(clinicaltrials.gov)
- P1, N=137; Recruiting -> Completed
Trial completion • Dyslipidemia
1 to 1
Of
1
Go to page
1